Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?
par Burstein, Harold J;Piccart-Gebhart, Martine
;Perez, Edith A;Hortobagyi, Gabriel N.;Wolmark, Norman;Albain, Kathy S;Norton, Larry;Winer, Eric P;Hudis, Clifford
Référence Journal of clinical oncology, 30, 18, page (2179-2182)
Publication Publié, 2012-06

Référence Journal of clinical oncology, 30, 18, page (2179-2182)
Publication Publié, 2012-06
Article révisé par les pairs
Titre: |
|
Auteur: | Burstein, Harold J; Piccart-Gebhart, Martine; Perez, Edith A; Hortobagyi, Gabriel N.; Wolmark, Norman; Albain, Kathy S; Norton, Larry; Winer, Eric P; Hudis, Clifford |
Informations sur la publication: | Journal of clinical oncology, 30, 18, page (2179-2182) |
Statut de publication: | Publié, 2012-06 |
Sujet CREF: | Cancérologie |
MeSH keywords: | Anthracyclines -- administration & dosage -- adverse effects |
Antibodies, Monoclonal, Humanized -- administration & dosage | |
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use | |
Breast Neoplasms -- drug therapy -- metabolism | |
Chemotherapy, Adjuvant | |
Heart Failure -- chemically induced | |
Humans | |
Molecular Targeted Therapy | |
Receptor, erbB-2 -- immunology -- metabolism | |
Note générale: | Journal Article |
Research Support, Non-U.S. Gov't | |
SCOPUS: no.j | |
Langue: | Anglais |
Identificateurs: | urn:issn:0732-183X |
info:doi/10.1200/JCO.2012.42.0695 | |
info:pii/JCO.2012.42.0695 | |
info:scp/84864018416 | |
info:pmid/22614986 |